Search results for "Dopamine receptor binding"

showing 2 items of 2 documents

Acute effect of intravenously applied alcohol in the human striatal and extrastriatal D2 /D3 dopamine system

2016

Investigations on the acute effects of alcohol in the human mesolimbic dopamine D2 /D3 receptor system have yielded conflicting results. With respect to the effects of alcohol on extrastriatal D2 /D3 dopamine receptors no investigations have been reported yet. Therefore we applied PET imaging using the postsynaptic dopamine D2 /D3 receptor ligand [18 F]fallypride addressing the question, whether intravenously applied alcohol stimulates the extrastriatal and striatal dopamine system. We measured subjective effects of alcohol and made correlation analyses with the striatal and extrastriatal D2 /D3 binding potential. Twenty-four healthy male μ-opioid receptor (OPRM1)118G allele carriers underw…

0301 basic medicinePharmacologymedicine.medical_specialtyMedicine (miscellaneous)D3 dopamine receptor binding03 medical and health sciencesPsychiatry and Mental health030104 developmental biology0302 clinical medicineEndocrinologyFallyprideDopamine receptorDopamine receptor D3DopamineInternal medicineDopamine receptor D2medicineOrbitofrontal cortexPsychologyPrefrontal cortexNeuroscience030217 neurology & neurosurgerymedicine.drugAddiction Biology
researchProduct

Savoxepine: invalidation of an "atypical" neuroleptic response pattern predicted by animal models in an open clinical trial with schizophrenic patien…

1991

The new tetracyclic compound savoxepine exhibits potent antidopaminergic effects with preferential activity in the hippocampus as compared to striatum in rat brain. As a result of behavioural animal models and regional differences in dopamine receptor binding characteristics, it has been suggested to possess an "atypical" neuroleptic response pattern. In an open clinical trial, savoxepine was administered to 12 in-patients suffering from paranoid schizophrenia and schizophreniform disorder (DSM-III). Eight patients were treated with a stable dose of 0.5 mg per day throughout the study, while in the remaining patients higher doses up to 20 mg/day were administered. Mean total BPRS scores and…

AdultMalePsychosisParanoid schizophreniamedicine.medical_treatmentPharmacologyExtrapyramidal symptomsBasal Ganglia DiseasesmedicineHumansSchizophreniform disorderAntipsychoticAgedPharmacologyPsychiatric Status Rating ScalesDopamine antagonistDopamine receptor bindingMiddle Agedmedicine.diseaseEnzymesDisease Models AnimalSchizophreniaDibenzoxazepinesSchizophreniaFemaleSchizophrenic Psychologymedicine.symptomPsychologymedicine.drugAntipsychotic AgentsPsychopharmacology
researchProduct